Summary: Cigna Healthcare modified its authorized generics coverage policy (A008), effective April 16, 2026. Here's what billing teams need to know before that date.
Authorized generics sit in an unusual position in the pharmacy-meets-medical-billing world. They're brand-name drugs sold under a generic label — same formulation, same manufacturer, different price point. When Cigna Healthcare updates the policy governing how these products are covered and processed, it ripples through pharmacy benefit coordination, medical claims, and prior authorization workflows alike. This policy does not list specific CPT or HCPCS codes in the available data, so the focus here is on coverage logic, billing implications, and what your team should do before the April 16, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Authorized Generics – A008 |
| Policy Code | A008 |
| Change Type | Modified |
| Effective Date | April 16, 2026 |
| Impact Level | Medium |
| Specialties Affected | Pharmacy billing, specialty drug programs, managed care contracting, revenue cycle |
| Key Action | Review your authorized generic dispensing and billing workflows against the updated A008 policy before April 16, 2026 |
Cigna Authorized Generics Coverage Policy: What A008 Governs and Why It Matters in 2026
The Cigna authorized generics coverage policy under A008 governs how Cigna treats authorized generic drugs when processing claims. An authorized generic is a brand-name drug that a manufacturer sells — or licenses to another company to sell — under a generic drug application. The FDA doesn't require a separate approval. The drug is chemically identical to the brand.
That matters for billing because payers don't always treat authorized generics the same way they treat traditional generics. Some plans apply brand-name cost-sharing tiers. Others apply generic tiers. How Cigna classifies these products under A008 determines what your patients pay, what gets flagged for prior authorization, and how your pharmacy or medical claims adjudicate.
When Cigna modifies A008, it typically adjusts tier placement logic, medical necessity criteria for coverage exceptions, or the rules around substitution. Any of those changes affects reimbursement, patient cost-sharing, and claim denial patterns. The real issue here is formulary alignment — if your team coordinates pharmacy and medical benefits, a shift in authorized generic policy creates reconciliation work on both sides.
Cigna A008 Coverage Criteria and Medical Necessity Requirements 2026
The available policy data for A008 does not include a published line-by-line summary of the specific criteria changes made in this April 2026 modification. That's worth saying plainly, because it changes what your team should do: go directly to the source at Cigna's policy portal and pull the current policy document before April 16, 2026.
That said, here's what the A008 framework historically governs — and what any modification to it likely touches.
Tier placement and formulary status. Cigna's formulary determines whether an authorized generic is processed at the generic tier or brand tier. A modification to A008 can change that tier assignment. If your patients are currently paying generic cost-sharing on a product that moves to brand tier under the updated policy, expect patient out-of-pocket to increase and benefit exceptions to spike.
Medical necessity criteria for brand-name exceptions. When a patient needs the brand instead of the authorized generic — or vice versa — Cigna requires medical necessity documentation. This is where prior authorization intersects directly with A008. A modification to the coverage policy can tighten or loosen those criteria. If criteria tighten, your team will need more robust clinical documentation in the prior auth submission to avoid a claim denial.
Substitution rules. Some authorized generics are subject to mandatory substitution at the pharmacy level. Others are not. A008 governs Cigna's rules around when substitution is required and when a prescriber's brand-necessary notation holds. If those rules change in this modification, your prescribers need to know — because a dispense-as-written notation that worked before April 16, 2026 may not carry the same weight after.
Medical necessity determinations under this coverage policy turn on documentation quality. Your prescribers' notes need to address why a specific formulation is required. Generic and name do not equal clinical equivalence in every patient case, and Cigna's reviewers know that. Give them a reason in the record, not just a preference in the note.
Cigna A008 Exclusions and Non-Covered Indications
The available policy data does not specify exclusions or experimental designations for this modification. However, authorized generic policies typically exclude coverage in specific circumstances.
Off-formulary authorized generics. If a drug hasn't been reviewed and added to Cigna's formulary — even as an authorized generic — it won't adjudicate as covered. Don't assume FDA approval equals formulary placement. It doesn't.
Compounded versions of authorized generics. Compounded drugs that replicate an authorized generic formulation are typically excluded. If your patients are receiving compounded versions of a drug that has an authorized generic on formulary, those claims will likely be denied under the medical benefit and will not cross over cleanly to pharmacy processing.
Step therapy non-compliance. Some authorized generics sit behind step therapy requirements. If a patient hasn't tried the required prior step, coverage is denied regardless of medical necessity claims. This is a frequent source of claim denial that teams underestimate until it shows up in their AR aging.
If you're unsure how Cigna's A008 modification interacts with your specific drug mix, talk to your compliance officer before the April 16, 2026 effective date.
Coverage Indications at a Glance
Because the available policy data does not include a published indications table for this A008 modification, the table below reflects the general authorized generic coverage framework. Confirm each line against the actual A008 policy document before billing under the updated rules.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Authorized generic on Cigna formulary, generic tier | Covered | Not specified in available data | Standard adjudication, no prior auth typically required |
| Brand-name drug with authorized generic available — brand requested | Covered with conditions | Not specified in available data | Medical necessity documentation and prior authorization typically required |
| Authorized generic — mandatory substitution applicable | Covered (generic only) | Not specified in available data | Dispense-as-written notations may not override substitution rules under A008 |
| Off-formulary authorized generic | Not Covered | Not specified in available data | Formulary exception process required |
| Compounded version of authorized generic | Not Covered | Not specified in available data | Does not qualify as authorized generic under FDA definition |
This table is directional. The specific coverage status for each scenario under the April 2026 modification may differ. Pull the actual A008 document and reconcile these rows against the current policy language.
Cigna Authorized Generics Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the updated A008 policy document now. Don't wait until April 16, 2026. Go to Cigna's policy portal and download the current version of A008. Compare it line by line against the previous version. The changes that matter most are in tier placement rules and prior authorization criteria. |
| 2 | Audit your formulary-dependent claims for affected drugs. Identify every drug in your billing mix that Cigna has classified as an authorized generic. Cross-reference against the updated A008 tier assignments. Any drug that moves from generic to brand tier needs a workflow adjustment before the effective date. |
| 3 | Update your prior authorization checklists. If A008 tightens medical necessity criteria for brand exceptions or authorized generic exceptions, your prior auth submission templates need to reflect that. Build in the documentation requirements now so your team isn't scrambling after a denial. |
| 4 | Brief your prescribers on substitution rule changes. Authorized generic billing issues often start at the prescription level, not the billing level. If A008 modifies substitution requirements, your prescribers need to know what their dispense-as-written notations can and can't accomplish under the updated coverage policy. Send a one-page summary before April 16, 2026. |
| 5 | Review your coordination of benefits workflows. If you process both medical and pharmacy claims for the same patients, authorized generic changes create reconciliation exposure. A drug that adjudicates differently under the updated A008 billing guidelines may create duplicate denial flags or incorrect patient liability calculations. Check your crossover logic before the change goes live. |
| 6 | Set up denial tracking for A008-related codes starting April 16. Create a filter in your claim denial management system for authorized generic-related denials. Track denial reasons by drug, prescriber, and benefit type for the first 60 days after the effective date. Early patterns tell you where the policy change is hitting hardest. |
| 7 | If your drug mix is complex or your patient population is high-acuity, loop in your billing consultant. Authorized generics policy changes look simple on paper and get complicated fast in practice. A consultant who knows Cigna Healthcare's adjudication patterns will save you more in avoided denials than their fee costs. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Authorized Generics Under Cigna A008
The available policy data for Cigna A008 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is consistent with how pharmacy-oriented payer policies are typically structured — they govern formulary and coverage logic rather than procedure code billing.
That does not mean codes are irrelevant to your team. Here's where codes enter the picture under authorized generic policies:
Medical benefit drug claims. Some authorized generics are billed on the medical benefit rather than the pharmacy benefit — particularly injectable and infusion drugs. These claims use HCPCS J-codes or Q-codes depending on the drug and the setting. If A008 changes how Cigna adjudicates a drug that your team bills under the medical benefit, the HCPCS code you're using doesn't change, but the coverage and prior authorization rules around it do.
Specialty pharmacy coordination. For specialty drugs with authorized generic equivalents, prior authorization requests submitted under the pharmacy benefit reference drug-specific identifiers (NDC numbers) rather than CPT codes. A008 changes may affect which NDCs qualify for generic-tier processing.
Review the full A008 policy document for any drug-specific or NDC-level guidance included in the April 2026 modification. If Cigna has updated the list of drugs subject to A008's authorized generic rules, that list — not a CPT table — is what your team needs to work from.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.